28 Advanced Solid Tumors Clinical Trials in Pittsburgh, PA (2026)

Q: How do I join a clinical trial in Pittsburgh?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Pittsburgh research site will contact you.

Recruiting Advanced Solid Tumors Studies in Pittsburgh

NCT06805461Recruiting

PumaRx Registry Trial

This study is a multicenter, observational, post-marketing, registry study designed to track the safety and performance of the RenovoCath® device and assess survival outcomes in patients diagnosed wit...

Pittsburgh, PA1,000 participantsRenovoRx

View Study Details

NCT05867420Recruiting

A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.

The study is a dose-escalation and dose-expansion study to evaluate the safety, tolerability, and pharmacokinetics of ASKG915 as a single agent or in combination with standard of care (SOC) in patient...

Pittsburgh, PAPHASE1594 participantsAskGene Pharma, Inc.

View Study Details

NCT03686124Recruiting

ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors

The study's purpose is to establish the safety and tolerability of IMA203/IMA203CD8 products with or without combination with nivolumab in patients with solid tumors that express preferentially expres...

Pittsburgh, PAPHASE1375 participantsImmatics US, Inc.

View Study Details

NCT06730750Recruiting

A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors

This is a study of BMS-986490 as a monotherapy and in combination with bevacizumab in participants with select advanced solid tumors known to express CEACAM5....

Pittsburgh, PAPHASE1360 participantsBristol-Myers Squibb

View Study Details

NCT05684965Recruiting

XTX301 in Patients With Advanced Solid Tumors

This is a first-in-human, multicenter, Phase 1/2, open-label study designed to evaluate the safety and tolerability of XTX301 as monotherapy in patients with advanced solid tumors....

Pittsburgh, PAPHASE1358 participantsXilio Development, Inc.

View Study Details

NCT06130553Recruiting

A Study of AZD3470, a PRMT5 Inhibitor, in Patients With MTAP Deficient Advanced/Metastatic Solid Tumors

This is a first time in human (FTiH) Phase I/IIa, open-label, multi-centre study of AZD3470 in participants with advanced or metastatic solid tumors with MTAP deficiency. The study consists of several...

Pittsburgh, PAPHASE1334 participantsAstraZeneca

View Study Details

NCT07160725Recruiting

A Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid Tumors

A phase 1/2a, open-label, first-in-human study mainly aimed to evaluate the safety and tolerability of BMS-986517 in participants with solid tumors...

Pittsburgh, PAPHASE1315 participantsBristol-Myers Squibb

View Study Details

NCT07335497Recruiting

CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors

The purpose of this study is to determine the safety and tolerability of monotherapy CR-001 and identify the maximum tolerated dose (MTD), and/or optimal biologic dose and Recommended Phase 2 Dose(s) ...

Pittsburgh, PAPHASE1290 participantsCrescent Biopharma, Inc.

View Study Details

NCT05753722Recruiting

A First-in-human Study of PRTH-101 Monotherapy +/- Pembrolizumab in Subjects With Advanced Malignancies

The goal of this Open-Label Study is to evaluate the safety and tolerability of PRTH-101 alone or in combination with pembrolizumab in adults with advance or metastatic solid tumors....

Pittsburgh, PAPHASE1270 participantsIncendia Therapeutics

View Study Details

NCT04777994Recruiting

Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors

The study will assess the safety, PK, PD, and preliminary efficacy of ABBV-CLS-484 as monotherapy and in combination with a PD-1 targeting agent or with a or a vascular endothelial growth factor recep...

Pittsburgh, PAPHASE1248 participantsCalico Life Sciences LLC

View Study Details

NCT06413680Recruiting

A First-In Human (FIH) Trial to Find Out if REGN10597 is Safe and How Well it Works for Adult Participants With Advanced Solid Organ Malignancies

This study is researching an experimental drug called REGN10597 (called "study drug"). The study is focused on patients with certain solid tumors that are in an advanced stage. The aim of the study i...

Pittsburgh, PAPHASE1240 participantsRegeneron Pharmaceuticals

View Study Details

NCT06480552Recruiting

An Open-label Dose Escalation/Expansion Trial to Evaluate the Safety and Anti-tumor Activity of TEV-56278 Alone or in Combination With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors

The primary objectives of this trial are to: * Characterize the safety and tolerability of TEV-56278 * Determine the Recommended Phase 2 Dose (RP2D) * Evaluate antitumor activity of TEV-56278 (Part 2...

Pittsburgh, PAPHASE1240 participantsTeva Branded Pharmaceutical Products R&D LLC

View Study Details

NCT07141706Recruiting

A Study of DB-1317 in Selected Advanced/Metastatic Solid Tumors

This is a multicenter, open-label, multiple-dose, FIH Phase 1a/1b study. Phase 1a adopts an accelerated titration design and a BOIN design to identify the MTD or MAD of DB-1317; Phase 1b includes up t...

Pittsburgh, PAPHASE1233 participantsDualityBio Inc.

View Study Details

NCT06795412Recruiting

Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors

The primary objective of this study is to determine the recommended Phase 2 doses (RP2D(s)) and maximum tolerated dose (MTD) of PYX-201 in combination with pembrolizumab for participants with advanced...

Pittsburgh, PAPHASE1220 participantsPyxis Oncology, Inc

View Study Details

NCT06060613Recruiting

Safety and Efficacy of OBX-115 in Advanced Solid Tumors

This is a study to investigate the safety and efficacy of an investigational OBX-115 regimen in adult participants with advanced solid tumors....

Pittsburgh, PAPHASE1208 participantsObsidian Therapeutics, Inc.

View Study Details

NCT04064359Recruiting

Safety and Preliminary Efficacy of OBT076 in Recurrent/Metastatic CD205+ Solid Tumors

The purpose of this study is to evaluate OBT076, which is a drug that combines an antibody with an anti-cancer drug. This class of drugs are called Antibody-Drug Conjugates (ADC). Antibodies are norma...

Pittsburgh, PAPHASE1200 participantsOxford BioTherapeutics Ltd

View Study Details

NCT05877430Recruiting

Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer

Study CJB-101-01 will be conducted at multiple centers in the USA and Republic of Korea as an open-label safety and preliminary efficacy study of CJRB-101 in combination with pembrolizumab in subjects...

Pittsburgh, PAPHASE1160 participantsCJ Bioscience, Inc.

View Study Details

NCT06462794Recruiting

First In Human Study of CX-801 in Advanced Solid Tumors

The purpose of this first-in-human study, CTMX-801-101, is to characterize the safety, tolerability, and antitumor activity of CX-801 as monotherapy and in combination with pembrolizumab in adult part...

Pittsburgh, PAPHASE1121 participantsCytomX Therapeutics

View Study Details

NCT06249048Recruiting

Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab

Phase 1/2, Open-label, Multi-center, First-in-human Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of STX-001 Delivered by Intratumoral Injection in Pati...

Pittsburgh, PAPHASE1108 participantsStrand Therapeutics Inc.

View Study Details

NCT06014502Recruiting

Study to Evaluate IMGS-001 Treatment in Patients With Relapsed or Refractory Advanced Solid Tumors

The purpose of this Phase 1a/1b clinical trial is to test the safety of an investigational drug called IMGS-001 and to determine how well it can work in treating patients with advanced solid tumors th...

Pittsburgh, PAPHASE1105 participantsImmunoGenesis

View Study Details

NCT06171750Recruiting

Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors

This is a Phase 1, multicenter, open-label dose escalation study to determine the safety and tolerability of intratumoral (IT) injection of tolododekin alfa (ANK-101) in participants with advanced sol...

Pittsburgh, PAPHASE197 participantsAnkyra Therapeutics, Inc

View Study Details

NCT06730347Recruiting

A Study of Lorigerlimab in Participants With Advanced Solid Tumors

Study CP-MGD019-03 is an open-label study of lorigerlimab in participants with platinum-resistant ovarian cancer (PROC) or clear cell gynecologic cancer (CCGC). Approximately 60 participants will be e...

Pittsburgh, PAPHASE280 participantsMacroGenics

View Study Details

NCT07115043Recruiting

A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors

A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors...

Pittsburgh, PAPHASE160 participantsAstraZeneca

View Study Details

NCT06444815Recruiting

A Study of VET3-TGI in Patients With Solid Tumors

VET3-TGI is an oncolytic immunotherapy designed to treat advanced cancers. VET3-TGI has not been given to human patients yet, and the current study is designed to find a safe and effective dose of VET...

Pittsburgh, PAPHASE160 participantsKaliVir Immunotherapeutics

View Study Details

NCT04469530Recruiting

Sirolimus in Combination With Metronomic Chemotherapy in Children With High-Risk Solid Tumors

The primary objective of this study is to improve the 2-year progression-free survival in children with high-risk solid tumors who are administered a maintenance regimen with continuous sirolimus admi...

Pittsburgh, PAPHASE255 participantsEmory University

View Study Details

NCT04890613Recruiting

Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation

This is an open-label, multi-center, phase 1b study designed to determine a tolerable dose of CX-5461 administered by IV infusion on Day 1 and Day 8 of a 28-day cycle in patients with selected solid t...

Pittsburgh, PAPHASE152 participantsSenhwa Biosciences, Inc.

View Study Details

NCT04370587Recruiting

A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors

This is a Phase 1/2a, open-label, study to evaluate the safety and preliminary efficacy of intratumoral T3011 given alone and in combination with intravenous pembrolizumab in partients with advanced o...

Pittsburgh, PAPHASE130 participantsImmVira Pharma Co. Ltd

View Study Details

NCT05645523Recruiting

Indocyanine Green (ICG) Guided Sentinel Lymph Node Mapping for Pediatric Visceral Solid Tumors

The purpose of the study is to find out the usefulness and safety of a dye called Indocyanine Green (ICG for short). This dye will be used to help the surgeon find lymph nodes draining solid tumors in...

Pittsburgh, PAEARLY_PHASE125 participantsSt. Jude Children's Research Hospital

View Study Details

About Advanced Solid Tumors Clinical Trials in Pittsburgh

Advanced solid tumors refer to cancers that have grown beyond the original site or spread to distant organs. Many clinical trials enroll patients with various types of advanced solid tumors to test novel therapies. These trials often investigate immunotherapy, targeted therapy, and combination approaches.

There are currently 28 advanced solid tumors clinical trials recruiting participants in Pittsburgh, PA. These studies are seeking a combined 6,438 participants. Research is being sponsored by RenovoRx, AskGene Pharma, Inc., Immatics US, Inc. and 23 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Advanced Solid Tumors Clinical Trials in Pittsburgh — FAQ

Are there advanced solid tumors clinical trials in Pittsburgh?

Yes, there are 28 advanced solid tumors clinical trials currently recruiting in Pittsburgh, PA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Pittsburgh?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Pittsburgh research site will contact you about next steps.

Are clinical trials in Pittsburgh free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Pittsburgh studies also compensate for your time and travel.

What advanced solid tumors treatments are being tested?

The 28 active trials in Pittsburgh are testing new therapies including novel drugs, biologics, and treatment approaches for advanced solid tumors.

Data updated July 17, 2026 from ClinicalTrials.gov